J&J discussing breaking up Actelion in an acquisition, say sources: Reuters

Johnson & Johnson (JNJ.N) is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd (ATLN.S) that would separate its commercialized portfolio from its research and development (R&D) assets, sources told Reuters.

DealsNorth AmericaUSBriefs